Information:
Fel:
ID
15305
Beskrivning
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent; ODM derived from: https://clinicaltrials.gov/show/NCT01511198
Länk
https://clinicaltrials.gov/show/NCT01511198
Nyckelord
Versioner (1)
- 2016-05-25 2016-05-25 -
Uppladdad den
25 maj 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes NCT01511198
Eligibility Diabetes NCT01511198
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01511198
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
type 2 diabetic
Item
type 2 diabetic
boolean
C0011860 (UMLS CUI [1])
oral hypoglycaemic agent
Item
treated with oha (oral hypoglycaemic agent monotherapy for at least 3 months. prior use of metformin is allowed
boolean
C0359086 (UMLS CUI [1])
BMI
Item
body mass index (bmi) between 27.0-42.0 kg/m^2 (inclusive)
boolean
C1305855 (UMLS CUI [1])
hba1c
Item
hba1c maximum 10% based on analysis from central laboratory
boolean
C0019018 (UMLS CUI [1])
cardiac problems
Item
cardiac problems
boolean
C0262402 (UMLS CUI [1])
untreated hypertension
Item
uncontrolled treated/untreated hypertension
boolean
C0020538 (UMLS CUI [1])
proliferative retinopathy or known autonomic neuropathy
Item
proliferative retinopathy or known autonomic neuropathy
boolean
C0339467 (UMLS CUI [1])
C0259749 (UMLS CUI [2])
C0259749 (UMLS CUI [2])
severe hypoglycemia
Item
recurrent severe hypoglycemia as judged by the investigator
boolean
C0020615 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])
allergy to trial product
Item
known or suspected allergy to trial product or related products
boolean
C0020517 (UMLS CUI [1,1])
C3854006 (UMLS CUI [1,2])
C3854006 (UMLS CUI [1,2])
use of any drug contraindicated
Item
use of any drug (except for ohas), which in the investigators opinion could interfere with the glucose level or body weight or any contraindication to metformin use or intolerance to metformin 1000 mg (prior to trial entry or during run-in period). stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
boolean
C3845816 (UMLS CUI [1])
abuse of alcohol or narcotics
Item
known or suspected abuse of alcohol or narcotics
boolean
C0038586 (UMLS CUI [1])
thiazolidinediones or chronic daily use of insulin
Item
current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
boolean
C1257987 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
C0021641 (UMLS CUI [2])
thyroid stimulating hormone
Item
tsh (thyroid stimulating hormone) below 0.2 or above 15 u/ml
boolean
C0202230 (UMLS CUI [1])
type 1 diabetes
Item
type 1 or other specific causes of diabetes
boolean
C0011854 (UMLS CUI [1])